Transgene SA (TNG.PA)
EUR 0.71
(-1.8%)
EUR 0.71
(-1.8%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.25 Million EUR | -48.67% |
| 2022 | 2.44 Million EUR | -36.29% |
| 2021 | 3.84 Million EUR | -27.24% |
| 2020 | 5.28 Million EUR | -68.3% |
| 2019 | 16.66 Million EUR | -57.14% |
| 2018 | 38.87 Million EUR | -7.82% |
| 2017 | 42.17 Million EUR | -6.78% |
| 2016 | 45.24 Million EUR | 24.25% |
| 2015 | 36.4 Million EUR | 0.56% |
| 2014 | 36.2 Million EUR | 2.53% |
| 2013 | 35.31 Million EUR | 26.89% |
| 2012 | 27.83 Million EUR | 0.0% |
| 2011 | - EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| 2004 | 5.05 Million EUR | -8.7% |
| 2003 | 5.53 Million EUR | -5.98% |
| 2002 | 5.89 Million EUR | -5.73% |
| 2001 | 6.24 Million EUR | 0.5% |
| 2000 | 6.21 Million EUR | 8.42% |
| 1999 | 5.73 Million EUR | 40.3% |
| 1998 | 4.08 Million EUR | -5.4% |
| 1997 | 4.32 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 90 Thousand EUR | 0.0% |
| 2023 Q1 | 11.57 Million EUR | 372.44% |
| 2023 Q4 | 1.25 Million EUR | -92.17% |
| 2023 Q2 | 1.84 Million EUR | -84.1% |
| 2023 Q3 | 16.05 Million EUR | 772.55% |
| 2023 FY | 1.25 Million EUR | -48.67% |
| 2022 Q3 | 12.32 Million EUR | 285.1% |
| 2022 FY | 2.44 Million EUR | -36.29% |
| 2022 Q4 | 2.44 Million EUR | -80.13% |
| 2022 Q2 | 3.2 Million EUR | -78.97% |
| 2022 Q1 | 15.22 Million EUR | 295.99% |
| 2021 Q2 | 4.53 Million EUR | -73.02% |
| 2021 FY | 3.84 Million EUR | -27.24% |
| 2021 Q1 | 16.8 Million EUR | 218.08% |
| 2021 Q3 | 15.35 Million EUR | 238.74% |
| 2021 Q4 | 3.84 Million EUR | -74.97% |
| 2020 Q1 | 27.54 Million EUR | 65.32% |
| 2020 Q2 | 16.1 Million EUR | -41.56% |
| 2020 Q3 | 17.1 Million EUR | 6.22% |
| 2020 FY | 5.28 Million EUR | -68.3% |
| 2020 Q4 | 5.28 Million EUR | -69.11% |
| 2019 Q2 | 28.85 Million EUR | -41.03% |
| 2019 FY | 16.66 Million EUR | -57.14% |
| 2019 Q3 | 27.34 Million EUR | -5.22% |
| 2019 Q4 | 16.66 Million EUR | -39.07% |
| 2019 Q1 | 48.93 Million EUR | 25.87% |
| 2018 FY | 38.87 Million EUR | -7.82% |
| 2018 Q2 | 39.32 Million EUR | -32.89% |
| 2018 Q1 | 58.6 Million EUR | 38.96% |
| 2018 Q4 | 38.87 Million EUR | -33.32% |
| 2018 Q3 | 58.29 Million EUR | 48.23% |
| 2017 Q4 | 42.17 Million EUR | -30.75% |
| 2017 Q2 | 42.32 Million EUR | -28.53% |
| 2017 FY | 42.17 Million EUR | -6.78% |
| 2017 Q3 | 60.89 Million EUR | 43.87% |
| 2017 Q1 | 59.22 Million EUR | 30.91% |
| 2016 FY | 45.24 Million EUR | 24.25% |
| 2016 Q3 | 61.86 Million EUR | 36.21% |
| 2016 Q2 | 45.41 Million EUR | -26.77% |
| 2016 Q1 | 62.02 Million EUR | 70.35% |
| 2016 Q4 | 45.24 Million EUR | -26.87% |
| 2015 Q2 | 44.52 Million EUR | -25.27% |
| 2015 FY | 36.4 Million EUR | 0.56% |
| 2015 Q4 | 36.4 Million EUR | -30.84% |
| 2015 Q3 | 52.64 Million EUR | 18.23% |
| 2015 Q1 | 59.57 Million EUR | 64.55% |
| 2014 Q4 | 36.2 Million EUR | -29.13% |
| 2014 Q3 | 51.09 Million EUR | 16.35% |
| 2014 FY | 36.2 Million EUR | 2.53% |
| 2014 Q2 | 43.91 Million EUR | -24.74% |
| 2014 Q1 | 58.34 Million EUR | 65.22% |
| 2013 Q1 | 45.97 Million EUR | 65.17% |
| 2013 FY | 35.31 Million EUR | 26.89% |
| 2013 Q4 | 35.31 Million EUR | -27.42% |
| 2013 Q3 | 48.65 Million EUR | 36.01% |
| 2013 Q2 | 35.77 Million EUR | -22.18% |
| 2012 FY | 27.83 Million EUR | 0.0% |
| 2012 Q4 | 27.83 Million EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q3 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2009 Q2 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2008 Q4 | - EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| 2005 Q2 | - EUR | 0.0% |
| 2004 FY | 5.05 Million EUR | -8.7% |
| 2004 Q4 | 5.05 Million EUR | 0.0% |
| 2004 Q2 | - EUR | 0.0% |
| 2004 Q1 | - EUR | -100.0% |
| 2003 Q3 | - EUR | 0.0% |
| 2003 Q4 | 5.53 Million EUR | 0.0% |
| 2003 Q2 | - EUR | 0.0% |
| 2003 FY | 5.53 Million EUR | -5.98% |
| 2003 Q1 | - EUR | -100.0% |
| 2002 Q4 | 5.89 Million EUR | 0.0% |
| 2002 Q2 | - EUR | 0.0% |
| 2002 Q1 | - EUR | -100.0% |
| 2002 FY | 5.89 Million EUR | -5.73% |
| 2002 Q3 | - EUR | 0.0% |
| 2001 Q3 | - EUR | 0.0% |
| 2001 Q4 | 6.24 Million EUR | 0.0% |
| 2001 FY | 6.24 Million EUR | 0.5% |
| 2001 Q1 | - EUR | -100.0% |
| 2001 Q2 | - EUR | 0.0% |
| 2000 Q1 | - EUR | -100.0% |
| 2000 FY | 6.21 Million EUR | 8.42% |
| 2000 Q3 | - EUR | 0.0% |
| 2000 Q4 | 6.21 Million EUR | 0.0% |
| 2000 Q2 | - EUR | 0.0% |
| 1999 FY | 5.73 Million EUR | 40.3% |
| 1999 Q4 | 5.73 Million EUR | 0.0% |
| 1998 FY | 4.08 Million EUR | -5.4% |
| 1998 Q4 | 4.08 Million EUR | 0.0% |
| 1997 FY | 4.32 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | 62.92% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 97.734% |
| Adocia SA | 13.08 Million EUR | 90.396% |
| Aelis Farma SA | 4.03 Million EUR | 68.871% |
| Biophytis S.A. | 8.27 Million EUR | 84.8% |
| Advicenne S.A. | 17.42 Million EUR | 92.786% |
| genOway Société anonyme | 7.23 Million EUR | 82.622% |
| IntegraGen SA | 1.12 Million EUR | -11.76% |
| Medesis Pharma S.A. | 1.2 Million EUR | -4.75% |
| Neovacs S.A. | 650 Thousand EUR | -93.385% |
| NFL Biosciences SA | 62.17 Thousand EUR | -1921.745% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 71.147% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | 53.733% |
| Sensorion SA | 2.86 Million EUR | 56.184% |
| Theranexus Société Anonyme | 3.64 Million EUR | 65.496% |
| TME Pharma N.V. | 1.16 Million EUR | -7.804% |
| Valbiotis SA | 6.87 Million EUR | 81.724% |
| TheraVet SA | 1.15 Million EUR | -8.374% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 86.03% |
| argenx SE | 18.1 Million EUR | 93.057% |
| BioSenic S.A. | 28.16 Million EUR | 95.536% |
| Celyad Oncology SA | 902 Thousand EUR | -39.357% |
| DBV Technologies S.A. | 13.01 Million USD | 90.345% |
| Galapagos NV | 9.59 Million EUR | 86.901% |
| Genfit S.A. | 70.17 Million EUR | 98.209% |
| GeNeuro SA | 7.73 Million EUR | 83.755% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | 76.256% |
| Innate Pharma S.A. | 39.89 Million EUR | 96.849% |
| Inventiva S.A. | 37.4 Million EUR | 96.64% |
| MaaT Pharma SA | 14.07 Million EUR | 91.069% |
| MedinCell S.A. | 58.96 Million EUR | 97.868% |
| Nanobiotix S.A. | 50.56 Million EUR | 97.514% |
| Onward Medical N.V. | 16.87 Million EUR | 92.551% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 90.816% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 97.256% |
| Oxurion NV | 12.33 Million EUR | 89.809% |
| Pharming Group N.V. | 155.29 Million EUR | 99.191% |
| Poxel S.A. | 46.9 Million EUR | 97.32% |
| GenSight Biologics S.A. | 18.42 Million EUR | 93.179% |
| Financière de Tubize SA | 79.2 Million EUR | 98.413% |
| UCB SA | 3.03 Billion EUR | 99.959% |
| Valneva SE | 208.81 Million EUR | 99.398% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -3207.895% |